Fingolimod
- Generic Name
- Fingolimod
- Brand Names
- Gilenya, Tascenso, Fingolimod Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C19H33NO2
- CAS Number
- 162359-55-9
- Unique Ingredient Identifier
- 3QN8BYN5QF
- Background
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.
- Indication
Fingolimod is indicated for the treatment of patients aged 10 and above with relapsing forms of multiple sclerosis, which may include clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
- Associated Therapies
- Alternative Treatment
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 281
- Registration Number
- NCT00333138
- Locations
- 🇬🇧
Novartis Investigational site, Newcastle upon Tyne, United Kingdom
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1272
- Registration Number
- NCT00289978
- Locations
- 🇹🇷
Gaziantep University School of Medicine, Neurology Department, Gaziantep, Turkey
🇦🇺The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
🇬🇷Athens Naval Hospital, Neurology Department, Athens, Greece
Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 684
- Registration Number
- NCT00239863
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 255
- Registration Number
- NCT00239798
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT00239876
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 396
- Registration Number
- NCT00239902
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 684
- Registration Number
- NCT00239785
Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 684
- Registration Number
- NCT00239811
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
- Conditions
- Kidney Transplantation
- First Posted Date
- 2004-12-21
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00099801
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
- Conditions
- Kidney Transplantation
- First Posted Date
- 2004-12-20
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 255
- Registration Number
- NCT00099749
- Locations
- 🇺🇸
SIU School of Medicine, Springfield, Illinois, United States
🇺🇸St. Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.